You are here

  • Home
  • Archive
  • Volume 61, Issue 12
  • Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Citation Tools

Article menu
Download PDFPDF
Original articles
Inflammatory bowel disease
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Hueber W, Sands BE, Lewitzky S, et al
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Gut 2012;61:1693-1700.